These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 12634464

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Samarium 153Sm lexidronam.
    Lamb HM, Faulds D.
    Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
    [Abstract] [Full Text] [Related]

  • 45. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
    Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA.
    J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
    [Abstract] [Full Text] [Related]

  • 46. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
    Dolezal J, Vizd'a J, Cermáková E.
    Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.
    Etchebehere EC, Pereira Neto CA, Lima MC, Santos Ade O, Ramos CD, Silva CM, Camargo EE.
    Sao Paulo Med J; 2004 Sep 02; 122(5):208-12. PubMed ID: 15558143
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. [Treatment of painful bony metastases with Samarium 153-EDTMP in prostate carcinoma].
    Mhiri A, Hassad R, Sellem A, Bahri H, Diakite R, Slim I, Mahersi M, Hammami H, Ben Adallah M, Ben Slimene MF.
    Tunis Med; 2007 Jul 02; 85(7):580-5. PubMed ID: 18064991
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.
    Sapienza MT, Ono CR, Guimarães MI, Watanabe T, Costa PA, Buchpiguel CA.
    Rev Hosp Clin Fac Med Sao Paulo; 2004 Dec 02; 59(6):321-8. PubMed ID: 15654484
    [Abstract] [Full Text] [Related]

  • 55. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium.
    Krishnamurthy GT, Krishnamurthy S.
    J Nucl Med; 2000 Apr 02; 41(4):688-91. PubMed ID: 10768570
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
    Sandeman TF, Budd RS, Martin JJ.
    Clin Oncol (R Coll Radiol); 1992 May 02; 4(3):160-4. PubMed ID: 1375094
    [Abstract] [Full Text] [Related]

  • 60. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.
    Menda Y, Bushnell DL, Williams RD, Miller S, Thomas MO.
    Clin Nucl Med; 2000 Sep 02; 25(9):698-700. PubMed ID: 10983757
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.